Aberrant activation of AMP-activated protein kinase remodels metabolic network in favor of cardiac glycogen storage.

AMP-activated protein kinase (AMPK) responds to impaired cellular energy status by stimulating substrate metabolism for ATP generation. Mutation of the gamma2 regulatory subunit of AMPK in humans renders the kinase insensitive to energy status and causes glycogen storage cardiomyopathy via unknown mechanisms. Using transgenic mice expressing one of the mutant gamma2 subunits (N488I) in the heart, we found that aberrant high activity of AMPK in the absence of energy deficit caused extensive remodeling of the substrate metabolism pathways to accommodate increases in both glucose uptake and fatty acid oxidation in the hearts of gamma2 mutant mice via distinct, yet synergistic mechanisms resulting in selective fuel storage as glycogen. Increased glucose entry in the gamma2 mutant mouse hearts was directed through the remodeled metabolic network toward glycogen synthesis and, at a substantially higher glycogen level, recycled through the glycogen pool to enter glycolysis. Thus, the metabolic consequences of chronic activation of AMPK in the absence of energy deficiency is distinct from those previously reported during stress conditions. These findings are of particular importance in considering AMPK as a target for the treatment of metabolic diseases.

[1]  B. Kemp,et al.  Genetic model for the chronic activation of skeletal muscle AMP-activated protein kinase leads to glycogen accumulation. , 2007, American journal of physiology. Endocrinology and metabolism.

[2]  N. Fujii,et al.  Muscle-specific overexpression of wild type and R225Q mutant AMP-activated protein kinase gamma3-subunit differentially regulates glycogen accumulation. , 2006, American journal of physiology. Endocrinology and metabolism.

[3]  J. Schneider,et al.  Characterization of the role of gamma2 R531G mutation in AMP-activated protein kinase in cardiac hypertrophy and Wolff-Parkinson-White syndrome. , 2006, American journal of physiology. Heart and circulatory physiology.

[4]  Sofia Martinsson,et al.  Opposite Transcriptional Regulation in Skeletal Muscle of AMP-activated Protein Kinase γ3 R225Q Transgenic Versus Knock-out Mice* , 2006, Journal of Biological Chemistry.

[5]  Ferhaan Ahmad,et al.  Increased &agr;2 Subunit–Associated AMPK Activity and PRKAG2 Cardiomyopathy , 2005, Circulation.

[6]  J. Balschi,et al.  Decreased Contractile and Metabolic Reserve in Peroxisome Proliferator–Activated Receptor-&agr;–Null Hearts Can Be Rescued by Increasing Glucose Transport and Utilization , 2005, Circulation.

[7]  J. Seidman,et al.  N488I Mutation of the γ2-Subunit Results in Bidirectional Changes in AMP-Activated Protein Kinase Activity , 2005 .

[8]  J. Seidman,et al.  Glycogen storage diseases presenting as hypertrophic cardiomyopathy. , 2005, The New England journal of medicine.

[9]  G. Taffet,et al.  Transgenic Mouse Model of Ventricular Preexcitation and Atrioventricular Reentrant Tachycardia Induced by an AMP-Activated Protein Kinase Loss-of-Function Mutation Responsible for Wolff-Parkinson-White Syndrome , 2005, Circulation.

[10]  B. Viollet,et al.  The alpha2-5'AMP-activated protein kinase is a site 2 glycogen synthase kinase in skeletal muscle and is responsive to glucose loading. , 2004, Diabetes.

[11]  B. Lorell,et al.  Mechanisms for Increased Glycolysis in the Hypertrophied Rat Heart , 2004, Hypertension.

[12]  G. Hjälm,et al.  The 5′-AMP-activated Protein Kinase γ3 Isoform Has a Key Role in Carbohydrate and Lipid Metabolism in Glycolytic Skeletal Muscle* , 2004, Journal of Biological Chemistry.

[13]  M. Birnbaum,et al.  AMP-activated protein kinase mediates ischemic glucose uptake and prevents postischemic cardiac dysfunction, apoptosis, and injury. , 2004, The Journal of clinical investigation.

[14]  J. Hedegaard,et al.  UDP‐Glucose pyrophosphorylase is upregulated in carriers of the porcine RN− mutation in the AMP‐activated protein kinase , 2004, Proteomics.

[15]  N. Fujii,et al.  Glucose Metabolism and Energy Homeostasis in Mouse Hearts Overexpressing Dominant Negative α2 Subunit of AMP-activated Protein Kinase* , 2003, Journal of Biological Chemistry.

[16]  Ferhaan Ahmad,et al.  Transgenic Mice Overexpressing Mutant PRKAG2 Define the Cause of Wolff-Parkinson-White Syndrome in Glycogen Storage Cardiomyopathy , 2003, Circulation.

[17]  Y. Hellsten,et al.  Regulation of 5'AMP-activated protein kinase activity and substrate utilization in exercising human skeletal muscle. , 2003, American journal of physiology. Endocrinology and metabolism.

[18]  B. Hansen,et al.  AMP kinase activation ameliorates insulin resistance induced by free fatty acids in rat skeletal muscle. , 2002, American journal of physiology. Endocrinology and metabolism.

[19]  Mohit M. Jain,et al.  Cardiac-Specific Overexpression of GLUT1 Prevents the Development of Heart Failure Attributable to Pressure Overload in Mice , 2002, Circulation.

[20]  J. Seidman,et al.  Constitutively active AMP kinase mutations cause glycogen storage disease mimicking hypertrophic cardiomyopathy. , 2002, The Journal of clinical investigation.

[21]  L. Fananapazir,et al.  Identification of a gene responsible for familial Wolff-Parkinson-White syndrome. , 2001, The New England journal of medicine.

[22]  L. Goodyear,et al.  Increased Adenosine Monophosphate–Activated Protein Kinase Activity in Rat Hearts With Pressure-Overload Hypertrophy , 2001, Circulation.

[23]  H. Watkins,et al.  Mutations in the gamma(2) subunit of AMP-activated protein kinase cause familial hypertrophic cardiomyopathy: evidence for the central role of energy compromise in disease pathogenesis. , 2001, Human molecular genetics.

[24]  W. Derave,et al.  Glycogen synthase localization and activity in rat skeletal muscle is strongly dependent on glycogen content , 2001, The Journal of physiology.

[25]  D. Carling,et al.  Phosphorylation and activation of heart PFK-2 by AMPK has a role in the stimulation of glycolysis during ischaemia , 2000, Current Biology.

[26]  P. Roach,et al.  Glycogen synthase sensitivity to insulin and glucose-6-phosphate is mediated by both NH2- and COOH-terminal phosphorylation sites. , 2000, Diabetes.

[27]  W. Winder,et al.  Activation of AMP-activated protein kinase increases mitochondrial enzymes in skeletal muscle. , 2000, Journal of applied physiology.

[28]  C. Rogel-Gaillard,et al.  A mutation in PRKAG3 associated with excess glycogen content in pig skeletal muscle. , 2000, Science.

[29]  N. Fujii,et al.  Activation of AMP-Activated Protein Kinase as a Unifying Coupling Mechanism , 2000 .

[30]  B. Lowell,et al.  Cardiac hypertrophy with preserved contractile function after selective deletion of GLUT4 from the heart. , 1999, The Journal of clinical investigation.

[31]  W. Winder,et al.  Chronic activation of 5'-AMP-activated protein kinase increases GLUT-4, hexokinase, and glycogen in muscle. , 1999, Journal of applied physiology.

[32]  M. Rider,et al.  Mechanisms of control of heart glycolysis. , 1998, European journal of biochemistry.

[33]  J. Ingwall,et al.  Impaired cardiac energetics in mice lacking muscle-specific isoenzymes of creatine kinase. , 1998, Circulation research.

[34]  S. E. Brodie New York, New York, USA , 1996 .

[35]  G. Lopaschuk,et al.  High Rates of Fatty Acid Oxidation during Reperfusion of Ischemic Hearts Are Associated with a Decrease in Malonyl-CoA Levels Due to an Increase in 5′-AMP-activated Protein Kinase Inhibition of Acetyl-CoA Carboxylase (*) , 1995, The Journal of Biological Chemistry.

[36]  R. Balaban,et al.  Nonglucose substrates increase glycogen synthesis in vivo in dog heart. , 1994, The American journal of physiology.

[37]  D. Hardie,et al.  Role of the AMP-activated protein kinase in the cellular stress response , 1994, Current Biology.

[38]  J. Robbins,et al.  Tissue-specific regulation of the alpha-myosin heavy chain gene promoter in transgenic mice. , 1991, The Journal of biological chemistry.

[39]  J. Gulick,et al.  Isolation and characterization of the mouse cardiac myosin heavy chain genes. , 1991, The Journal of biological chemistry.

[40]  G. Lyons,et al.  Developmental regulation of myosin gene expression in mouse cardiac muscle , 1990, The Journal of cell biology.

[41]  A. Sherry,et al.  Analysis of tricarboxylic acid cycle of the heart using 13C isotope isomers. , 1990, The American journal of physiology.

[42]  A. Sherry,et al.  Evaluation of carbon flux and substrate selection through alternate pathways involving the citric acid cycle of the heart by 13C NMR spectroscopy. , 1988, The Journal of biological chemistry.

[43]  D. E. Atkinson,et al.  Uridine diphosphate glucose synthase from calf liver: determinants of enzyme activity in vitro. , 1975, Biochemistry.

[44]  J. Passonneau,et al.  A comparison of three methods of glycogen measurement in tissues. , 1974, Analytical biochemistry.

[45]  J. Williamson GLYCOLYTIC CONTROL MECHANISMS. I. INHIBITION OF GLYCOLYSIS BY ACETATE AND PYRUVATE IN THE ISOLATED, PERFUSED RAT HEART. , 1965, The Journal of biological chemistry.

[46]  Oliver H. Lowry,et al.  Protein measurement with the Folin phenol reagent. , 1951, The Journal of biological chemistry.

[47]  J. Seidman,et al.  N488I mutation of the gamma2-subunit results in bidirectional changes in AMP-activated protein kinase activity. , 2005, Circulation research.

[48]  O. Pedersen,et al.  Chronic treatment with 5-aminoimidazole-4-carboxamide-1-beta-D-ribofuranoside increases insulin-stimulated glucose uptake and GLUT4 translocation in rat skeletal muscles in a fiber type-specific manner. , 2001, Diabetes.

[49]  B. Kemp,et al.  Dealing with energy demand: the AMP-activated protein kinase. , 1999, Trends in biochemical sciences.

[50]  D. Hardie,et al.  The AMP-activated protein kinase--fuel gauge of the mammalian cell? , 1997, European journal of biochemistry.

[51]  O. H. Lowry,et al.  A Collection of Metabolite Assays , 1993 .

[52]  J. A. Thomas,et al.  A rapid filter paper assay for UDPglucose-glycogen glucosyltransferase, including an improved biosynthesis of UDP-14C-glucose. , 1968, Analytical biochemistry.